Recovery is typically quick, with most people resuming normal activities within a week
Novel AOMs, largely based around incretin therapy, may exceed weight loss of 20% [10, 75], however, most trials evaluating their efficacy and safety were performed with younger adults, and those that include older adults often poorly define the number of participants in each age group
This early effect reflects semaglutide's direct activation of GLP-1 receptors in regions that regulate satiety signals
Common negative reports include increased injection site discomfort, slightly more GI upset (particularly during the first few weeks), and disappointment when the dramatic results promised by marketing materials do not materialize
It may be appealing to people who manage full schedules, experience long workdays, or want to maintain balance during active or high-stress periods
This is the maximum maintenance dose, which is used for long-term weight management